Brizio Moreno‐Jaime

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 268 citations · Full text

High response rate to low‐dose rituximab plus high‐dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia

David Gómez‐Almaguer, Luz Tarín‐Arzaga, Brizio Moreno‐Jaime et al. · European Journal Of Haematology · 2013 · 68 citations

Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-α in LLC-PK1 cells

Martha Imelda Maldonado Cervantes, Brizio Moreno‐Jaime, Juan Ramón Zapata‐Morales et al. · Journal of Physiology and Biochemistry · 2012 · 49 citations

Signal Transduction, Autocrine Modulation, Cell Regulation +8

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Annals of Oncology · 2021 · 18 citations

Medicine, Pathology, Lba51 Empower-lung 3 +6

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Tamta Makharadze, Ruben G.W. Quek, Tamar Melkadze et al. · Cancer · 2023 · 12 citations · Full text